|
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like
Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers
, one of the largest ketamine clinics in the country.
Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of
opportunities by investing in cutting-edge ideas.
The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the first psychedelic umbrella platform. It is currently a trusted source for those interested in psychedelic culture, education, treatments, and more.
While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.
The Big Problems Delic Is Addressing
- Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
- Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
- Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
- Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.
Investment Considerations
- Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research.
- The Vancouver-based company was formed in 2019 as the first psychedelic umbrella platform.
- The Delic self-sustaining Ecosystem covers three main areas: media, health, and science.
- On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media.
- An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services.
- University-led and FDA-approved studies are positioning North America as a leading region in the advancement of psychedelics for therapeutic, medical, and recreational use.
Additional Resources
|
|
RECENT COVERAGE
Important Clinical Trials That May Result in Psychedelic Legalization
August 16, 2022 3:00 PM
Initial studies have found that certain psychedelics have plenty of potential as treatments for mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder. Furthermore, activists across the country have put forth a variety of measures to decriminalize psychedelics, with cities such as Denver moving to
decriminalize all psychedelics.
But before psychedelics can be approved for widespread medical use, they will have to go through the clinical trial system
successfully. This process involves three phases: phase I trials where animals are used to test the efficacy and safety of drugs; phase 2 trials involving several dozen patients with a specific condition such as PTSD; phase 3 trials where the safety and efficacy of the drug are tested
in a large group of people, usually more than 100 patients.
Once a psychedelic has successfully advanced past the third phase of clinical trials, it will be well on its way to receiving approval from the U.S. Food and Drugs Administration (FDA). At the moment, there are
three pivotal phase 3 clinical trials that could significantly speed up the legalization of psychedelics in the United States.
|
